Gilead highlights Yescarta survival data in ASCO update

Gilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage greater use of the slow-growing therapy.

Updated results from the ZUMA-1 trial that underpinned the 2017 approval of Yescarta (axicabtagene ciloleucel) in relapsed or refractory large B-cell lymphoma show that patients are still seeing a clinical benefit two years later.